French-based biotechnology company GamaMabs Pharma has dosed the first patient in the Phase Ia/Ib study of GM102 to treat advanced gynecological cancer.

GM102 is a first-in-class, monoclonal antibody (mAb) targeting the anti-Müllerian human receptor II (AMHR2 / MISR2) characterising gynecological cancers.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It is based on the EMABling glyco-engineering technology, which activates its immune system cells to kill the tumour cells.

The company noted that the first administration of GM102 has taken place at the Jules Bordet Institute in Brussels, Belgium, with AMHR2-positive patients suffering from advanced pre-treated gynecological cancer.

"We are extremely pleased with the accrual rate at Jules Bordet, to which French centres will be soon aggregated."

The trial is primarily focused to evaluate the safety in the administration of GM102 and to determine a dose for future Phase Ib/II trials.

GamaMabs Pharma research and development vice-president Jean-François Prost said: “As this is the very first time an AMHR2-targeting drug is being tested in oncology patients, we are very excited about generating data that can guide us through the development of GM102 in Phase II.

“We are extremely pleased with the accrual rate at Jules Bordet, to which French centres will be soon aggregated.”

According to principal investigator of the study at the Jules Bordet Institute Ahmad Awada, the mechanism of GM102 can be leveraged to treat gynecological cancers, namely ovarian, endometrium and cervical, and can also improve the treatment of relapsing patients.

The first stage of the Phase Ia/Ib dose escalation study is expected to be completed by next year, following which the company is planning to commence the second stage of the study consisting of two expansion cohorts in gynecological cancers.